Stockscreener 앱 받기
1.87
9.76%
0.18
전일 마감가:
$1.69
열려 있는:
$1.72
하루 거래량:
320.43K
Relative Volume:
0.33
시가총액:
$250.28M
수익:
-
순이익/손실:
$-101.70M
주가수익비율:
-0.9862
EPS:
-1.8961
순현금흐름:
$-84.35M
1주 성능:
+16.67%
1개월 성능:
-5.84%
6개월 성능:
+27.05%
1년 성능:
+248.10%
1일 변동 폭
$1.71
$1.87
1주일 범위
$1.55
$1.91
52주 변동 폭
$0.404
$2.66
AIx 온콜로지 Stock (ALXO) Company Profile
명칭
Alx Oncology Holdings Inc
전화
650-466-7125
주소
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.86 | 227.41M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
426.25 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.03 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.26 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.67 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.01 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
AIx 온콜로지 Stock (ALXO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-19 | 개시 | Wells Fargo | Overweight |
| 2026-03-06 | 재개 | UBS | Buy |
| 2025-11-13 | 개시 | Jefferies | Buy |
| 2025-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-06 | 개시 | UBS | Buy |
| 2021-02-10 | 개시 | H.C. Wainwright | Buy |
| 2020-08-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 개시 | Credit Suisse | Outperform |
| 2020-08-11 | 개시 | Jefferies | Buy |
| 2020-08-11 | 개시 | Piper Sandler | Overweight |
모두보기
AIx 온콜로지 주식(ALXO)의 최신 뉴스
Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired Stock - Yahoo Finance
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 - Yahoo Finance
BioAffinity stock surges 113.8% in 3 months: What's driving the rally? - MSN
ALX Oncology (ALXO) amendment shows Millennium affiliates report 1.99M shares - Stock Titan
ALXO Stock Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALXO (ALX Oncology Holdings Inc.) reports narrow Q4 2025 EPS miss sending shares 0.6% lower on mild investor disappointment.Sector Perform - UBND thành phố Hải Phòng
Buy or Sell? | ALX Oncology Holdings Inc. posts 0.1% EPS miss, no revenue dataRevision Downgrade - Xã Thanh Hà
ALX Oncology (ALXO) Stock Analysis: Buy or Sell? | ALX Oncology Holdings Inc. posts 0.1% EPS miss, no revenue dataMoat - Cổng thông tin điện tử Tỉnh Sơn La
ALXO Financials: Income Statement, Balance Sheet & Cash Flow | Alx Oncology Holdings Inc - Stock Titan
ALX Oncology | ARS: Annual Report to Security Holders - Moomoo
[ARS] ALX ONCOLOGY HOLDINGS INC SEC Filing - Stock Titan
[DEF 14A] ALX ONCOLOGY HOLDINGS INC Definitive Proxy Statement - Stock Titan
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - Sahm
ALX Oncology (NASDAQ:ALXO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
ALXO PE Ratio & Valuation, Is ALXO Overvalued - Intellectia AI
Alx Oncology reports inducement grant as permitted by the Nasdaq Listing Rules - marketscreener.com
ALX Oncology (NASDAQ: ALXO) awards 800,000 options to chief officer - Stock Titan
ALX Oncology (ALXO) awards CMO 100,000 stock options at $1.68 - Stock Titan
Jeff Knight named reporting insider at ALX Oncology (NASDAQ: ALXO) with no trades - Stock Titan
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally? - The Globe and Mail
ALX Oncology Holdings Inc. Appoints Jeff Knight As Chief Development And Operating Officer, Effective April 13, 2026 - marketscreener.com
Stock Market Recap: Is ALX Oncology Holdings Inc a stock for growth or value investorsTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
ALX Oncology names Jeff Knight as chief development officer By Investing.com - Investing.com Australia
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer to Advance Cancer Therapy Pipeline 1 - Minichart
ALX Oncology names Jeff Knight as chief development officer - Investing.com
ALX Oncology Appoints Jeff Knight to Lead Development - TipRanks
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Bitget
Jeff Knight joins ALX Oncology (NASDAQ: ALXO) as development chief - Stock Titan
ALX brings in 30-year biotech veteran ahead of key cancer milestones - Stock Titan
Press Release: ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Moomoo
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Profit Recap: What are the risks of holding ALX Oncology Holdings Inc2026 Final Week & Trade Opportunity Analysis - baoquankhu1.vn
Retail Trends: Can ALX Oncology Holdings Inc reach all time highs this year2026 Market WrapUp & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
LRMR stock on the move: What sparked the 55% jump in the past month? - MSN
Geopolitics Watch: Is ALX Oncology Holdings Inc attractive at current valuation2026 Price Targets & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Block Trades: Will ALX Oncology Holdings Inc benefit from government policyPortfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
What is driving long-term growth of ALX Oncology (ALXO) Stock | Price at $1.83, Down 6.63%Crowd Risk Alerts - Xã Thanh Hà
ALXO Stock Price, Quote & Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALXO Technical Analysis & Stock Price Forecast - Intellectia AI
RLMD Stock Surges 42% in a Week: Here's What You Should Know - Eastern Progress
Certain Common Stock of ALX Oncology Holdings Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
AIx 온콜로지 (ALXO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
AIx 온콜로지 주식 (ALXO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pinto Shelly | SVP, FINANCE AND CAO |
Mar 19 '26 |
Sale |
2.17 |
903 |
1,960 |
86,805 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 18 '26 |
Sale |
2.27 |
565 |
1,283 |
87,708 |
| GOODMAN COREY S | Director |
Feb 02 '26 |
Buy |
1.57 |
3,184,713 |
4,999,999 |
8,453,038 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jan 06 '26 |
Sale |
1.11 |
3,925 |
4,357 |
88,273 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
0.83%
2.04%
자본화:
|
볼륨(24시간):